Autolus Therapeutics (AUTL) Cash from Operations (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Cash from Operations for 9 consecutive years, with 67323000.0 the latest figure, recorded in Q4 2025.

• Quarterly Cash from Operations fell 77.47% year-over-year to 67323000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 283568000.0 (down 37.47% YoY) and the FY2025 annual result came in at 283568000.0, down 37.47% from the prior year.
• Cash from Operations rose to 67323000.0 in Q4 2025 per AUTL's latest filing, from 67899000.0 in the prior quarter.
• Over the last five years, Cash from Operations for AUTL reached as high as 9158000.0 in Q4 2021 and fell as low as 76740000.0 in Q3 2024.
• A 5-year average of 43279750.0 and a median of 38040500.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2021 — Cash from Operations surged 66.97% — and 2024, when it slumped 90.95%.
• Year by year, Cash from Operations stood at 9158000.0 in 2021, then sank by 59.05% to 14566000.0 in 2022, then plunged by 70.49% to 24833000.0 in 2023, then sank by 52.76% to 37934000.0 in 2024, then plunged by 77.47% to 67323000.0 in 2025.
• According to Business Quant data, Cash from Operations over the past three periods registered 67323000.0, 67899000.0, and 72781000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.